Trial Profile
A prospective study to evaluate the effects of Tocilizumab on B-cell subpopulation to produce anti-CCP antibody for the treatment of Rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2017
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Therapeutic Use
- 09 Feb 2017 New trial record